

IN THE CLAIMS:

SPB

A2

-- 11. A method for preventing clotting in an extracorporeal blood circuit of a patient undergoing extracorporeal blood treatment comprising administering 0.001 to 10 mg of methyl O-(3,4-di-O-methyl-2,6-di-O-sulpho- α -D-glucopyranosyl)-(1 \rightarrow 4)-O-(3-O-methyl-2-O-sulpho- β -D-glucopyranosyl uronic acid)-(1 \rightarrow 4)-O-(2,3,6-tri-O-sulpho- α -D-glucopyranosyl)-(1 \rightarrow 4)-O-(3-O-methyl-2-O-sulpho- α -L-idopyranosyl uronic acid)-(1 \rightarrow 4)-2,3,6-tri-O-sulpho- α -D-glucopyranoside or a salt thereof per kg body weight of the patient. --

-- 12. A method for preventing clotting in an extracorporeal blood circuit of a patient undergoing extracorporeal blood treatment comprising administering 0.30 to 30 mg of methyl O-(3,4-di-O-methyl-2,6-di-O-sulpho- α -D-glucopyranosyl)-(1 \rightarrow 4)-O-(3-O-methyl-2-O-sulpho- β -D-glucopyranosyl uronic acid)-(1 \rightarrow 4)-O-(2,3,6-tri-O-sulpho- α -D-glucopyranosyl)-(1 \rightarrow 4)-O-(3-O-methyl-2-O-sulpho- α -L-idopyranosyl uronic acid)-(1 \rightarrow 4)-2,3,6-tri-O-sulpho- α -D-glucopyranoside or a salt thereof. --

Sub
J
-- 13. The method of claim 11, comprising administering a dodecasodium salt thereof. --

Sub
J
-- 14. The method of claim 12, comprising administering a dodecasodium salt thereof. --

Sub
J
A
-- 15. A method for preventing clotting in an extracorporeal blood circuit of a patient undergoing extracorporeal blood treatment comprising administering 0.001 to 10 mg of methyl O-(2,3,4-tri-O-methyl-6-O-sulpho- α -D-glucopyranosyl)-(1 \rightarrow 4)-O-(2,3-di-O-methyl- β -D-glucopyranosyl-uronic acid)-(1 \rightarrow 4)-O-(2,3,6-tri-O-sulpho- α -D-glucopyranosyl)-(1 \rightarrow 4)-O-(2,3-di-O-methyl- α -L-idopyranosyl uronic acid)-(1 \rightarrow 4)-2,3,6-tri-O-sulpho- α -D-glucopyranoside or a salt thereof per kg body weight of the patient. --

Sub
J
A
-- 16. A method for preventing clotting in an extracorporeal blood circuit of a patient undergoing extracorporeal blood treatment comprising administering 0.30 to 30 mg of a methyl O-(2,3,4-tri-O-methyl-6-O-sulpho- α -D-glucopyranosyl)-(1 \rightarrow 4)-O-(2,3-di-O-methyl- β -D-glucopyranosyl-uronic acid)-(1 \rightarrow 4)-O-(2,3,6-tri-O-sulpho- α -D-glucopyranosyl)-(1 \rightarrow 4)-O-(2,3-di-O-methyl- α -L-idopyranosyl uronic acid)-(1 \rightarrow 4)-2,3,6-tri-O-sulpho- α -D-glucopyranoside or a salt thereof. --

SB
EL

-- 17. The method of claim 15, comprising administering a nonasodium salt thereof. --

AZ

-- 18. The method of claim 16, comprising administering a nonasodium salt thereof. --